 | • レポートコード：D005-00754 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、非侵襲的がん診断の世界市場を広く調査・分析し、今後の市場展望をまとめております。非侵襲的がん診断の種類別市場規模（臨床化学、免疫化学/免疫測定、分子診断、その他）、用途別市場規模（固形がん、血液がん、肺がん、乳がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Precision Therapeutics, Inc. (U.S.)、Digene Corporation (U.S.)、AVIVA Biosciences Corporation (U.S.)、A&G Pharmaceutical, Inc. (U.S.)、Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)、Affymetrix Inc. (U.S.)、IVDiagnostics, Inc. (U.S.)、Laboratory Corporation of America Holdings (LabCorp) (U.S.)、BIOVIEW Inc. (U.S.)、Gen-Probe Incorporated (U.S.) ・地域別グローバル市場分析 2015年-2020年 ・非侵襲的がん診断の北米市場（アメリカ、カナダ、メキシコ） ・非侵襲的がん診断のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・非侵襲的がん診断のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・非侵襲的がん診断の南米市場（ブラジル、アルゼンチン） ・非侵襲的がん診断の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：臨床化学、免疫化学/免疫測定、分子診断、その他 ・用途別分析：固形がん、血液がん、肺がん、乳がん、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Noninvasive Cancer Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.7% in the forecast period of 2020 to 2025 and will expected to reach USD 127940 million by 2025, from USD 110450 million in 2019.
The Noninvasive Cancer Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Noninvasive Cancer Diagnostics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Noninvasive Cancer Diagnostics market has been segmented into:
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
By Application, Noninvasive Cancer Diagnostics has been segmented into:
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Noninvasive Cancer Diagnostics market presented in the report. This section sheds light on the sales growth of different regional and country-level Noninvasive Cancer Diagnostics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Noninvasive Cancer Diagnostics market.
The report offers in-depth assessment of the growth and other aspects of the Noninvasive Cancer Diagnostics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Noninvasive Cancer Diagnostics Market Share Analysis
Noninvasive Cancer Diagnostics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Noninvasive Cancer Diagnostics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Noninvasive Cancer Diagnostics sales, revenue and market share for each player covered in this report.
The major players covered in Noninvasive Cancer Diagnostics are:
Precision Therapeutics, Inc. (U.S.)
Digene Corporation (U.S.)
AVIVA Biosciences Corporation (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Affymetrix Inc. (U.S.)
IVDiagnostics, Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
BIOVIEW Inc. (U.S.)
Gen-Probe Incorporated (U.S.)
Table of Contents
1 Noninvasive Cancer Diagnostics Market Overview
1.1 Product Overview and Scope of Noninvasive Cancer Diagnostics
1.2 Classification of Noninvasive Cancer Diagnostics by Type
1.2.1 Global Noninvasive Cancer Diagnostics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Noninvasive Cancer Diagnostics Revenue Market Share by Type in 2019
1.2.3 Clinical Chemistry
1.2.4 Immunochemistry/Immunoassay
1.2.5 Molecular Diagnostics
1.2.6 Others
1.3 Global Noninvasive Cancer Diagnostics Market by Application
1.3.1 Overview: Global Noninvasive Cancer Diagnostics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Solid Tumors
1.3.3 Blood Cancer
1.3.4 Lung Cancer
1.3.5 Breast Cancer
1.3.6 Others
1.4 Global Noninvasive Cancer Diagnostics Market by Regions
1.4.1 Global Noninvasive Cancer Diagnostics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Noninvasive Cancer Diagnostics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Noninvasive Cancer Diagnostics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Noninvasive Cancer Diagnostics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Noninvasive Cancer Diagnostics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Noninvasive Cancer Diagnostics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Noninvasive Cancer Diagnostics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Precision Therapeutics, Inc. (U.S.)
2.1.1 Precision Therapeutics, Inc. (U.S.) Details
2.1.2 Precision Therapeutics, Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Precision Therapeutics, Inc. (U.S.) SWOT Analysis
2.1.4 Precision Therapeutics, Inc. (U.S.) Product and Services
2.1.5 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Digene Corporation (U.S.)
2.2.1 Digene Corporation (U.S.) Details
2.2.2 Digene Corporation (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Digene Corporation (U.S.) SWOT Analysis
2.2.4 Digene Corporation (U.S.) Product and Services
2.2.5 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.3 AVIVA Biosciences Corporation (U.S.)
2.3.1 AVIVA Biosciences Corporation (U.S.) Details
2.3.2 AVIVA Biosciences Corporation (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AVIVA Biosciences Corporation (U.S.) SWOT Analysis
2.3.4 AVIVA Biosciences Corporation (U.S.) Product and Services
2.3.5 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.4 A&G Pharmaceutical, Inc. (U.S.)
2.4.1 A&G Pharmaceutical, Inc. (U.S.) Details
2.4.2 A&G Pharmaceutical, Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 A&G Pharmaceutical, Inc. (U.S.) SWOT Analysis
2.4.4 A&G Pharmaceutical, Inc. (U.S.) Product and Services
2.4.5 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
2.5.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Details
2.5.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) SWOT Analysis
2.5.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Product and Services
2.5.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Affymetrix Inc. (U.S.)
2.6.1 Affymetrix Inc. (U.S.) Details
2.6.2 Affymetrix Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Affymetrix Inc. (U.S.) SWOT Analysis
2.6.4 Affymetrix Inc. (U.S.) Product and Services
2.6.5 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.7 IVDiagnostics, Inc. (U.S.)
2.7.1 IVDiagnostics, Inc. (U.S.) Details
2.7.2 IVDiagnostics, Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 IVDiagnostics, Inc. (U.S.) SWOT Analysis
2.7.4 IVDiagnostics, Inc. (U.S.) Product and Services
2.7.5 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
2.8.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Details
2.8.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) SWOT Analysis
2.8.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Product and Services
2.8.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.9 BIOVIEW Inc. (U.S.)
2.9.1 BIOVIEW Inc. (U.S.) Details
2.9.2 BIOVIEW Inc. (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 BIOVIEW Inc. (U.S.) SWOT Analysis
2.9.4 BIOVIEW Inc. (U.S.) Product and Services
2.9.5 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Gen-Probe Incorporated (U.S.)
2.10.1 Gen-Probe Incorporated (U.S.) Details
2.10.2 Gen-Probe Incorporated (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Gen-Probe Incorporated (U.S.) SWOT Analysis
2.10.4 Gen-Probe Incorporated (U.S.) Product and Services
2.10.5 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Noninvasive Cancer Diagnostics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Noninvasive Cancer Diagnostics Players Market Share
3.2.2 Top 10 Noninvasive Cancer Diagnostics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Noninvasive Cancer Diagnostics Revenue and Market Share by Regions
4.2 North America Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
4.3 Europe Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
4.5 South America Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
5 North America Noninvasive Cancer Diagnostics Revenue by Countries
5.1 North America Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
5.2 USA Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
5.3 Canada Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
5.4 Mexico Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
6 Europe Noninvasive Cancer Diagnostics Revenue by Countries
6.1 Europe Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
6.2 Germany Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
6.3 UK Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
6.4 France Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
6.5 Russia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
6.6 Italy Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Countries
7.1 Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
7.2 China Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
7.3 Japan Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
7.4 Korea Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
7.5 India Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
8 South America Noninvasive Cancer Diagnostics Revenue by Countries
8.1 South America Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
8.2 Brazil Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
8.3 Argentina Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Noninvasive Cancer Diagnostics by Countries
9.1 Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
9.3 UAE Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
9.4 Egypt Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
9.5 South Africa Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Noninvasive Cancer Diagnostics Revenue and Market Share by Type (2015-2020)
10.2 Global Noninvasive Cancer Diagnostics Market Forecast by Type (2019-2024)
10.3 Clinical Chemistry Revenue Growth Rate (2015-2025)
10.4 Immunochemistry/Immunoassay Revenue Growth Rate (2015-2025)
10.5 Molecular Diagnostics Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Noninvasive Cancer Diagnostics Market Segment by Application
11.1 Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2015-2020)
11.2 Noninvasive Cancer Diagnostics Market Forecast by Application (2019-2024)
11.3 Solid Tumors Revenue Growth (2015-2020)
11.4 Blood Cancer Revenue Growth (2015-2020)
11.5 Lung Cancer Revenue Growth (2015-2020)
11.6 Breast Cancer Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Noninvasive Cancer Diagnostics Market Size Forecast (2021-2025)
12.1 Global Noninvasive Cancer Diagnostics Market Size Forecast (2021-2025)
12.2 Global Noninvasive Cancer Diagnostics Market Forecast by Regions (2021-2025)
12.3 North America Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
12.4 Europe Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
12.6 South America Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Noninvasive Cancer Diagnostics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Noninvasive Cancer Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Noninvasive Cancer Diagnostics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Noninvasive Cancer Diagnostics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Precision Therapeutics, Inc. (U.S.) Corporate Information, Location and Competitors
Table 6. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 7. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 8. Precision Therapeutics, Inc. (U.S.) SWOT Analysis
Table 9. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 10. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Digene Corporation (U.S.) Corporate Information, Location and Competitors
Table 12. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 13. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2018-2019)
Table 14. Digene Corporation (U.S.) SWOT Analysis
Table 15. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 16. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. AVIVA Biosciences Corporation (U.S.) Corporate Information, Location and Competitors
Table 18. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 19. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 20. AVIVA Biosciences Corporation (U.S.) SWOT Analysis
Table 21. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 22. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. A&G Pharmaceutical, Inc. (U.S.) Corporate Information, Location and Competitors
Table 24. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 25. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 26. A&G Pharmaceutical, Inc. (U.S.) SWOT Analysis
Table 27. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 28. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Corporate Information, Location and Competitors
Table 30. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 31. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 32. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) SWOT Analysis
Table 33. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 34. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Affymetrix Inc. (U.S.) Corporate Information, Location and Competitors
Table 36. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 37. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 38. Affymetrix Inc. (U.S.) SWOT Analysis
Table 39. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 40. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. IVDiagnostics, Inc. (U.S.) Corporate Information, Location and Competitors
Table 42. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 43. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 44. IVDiagnostics, Inc. (U.S.) SWOT Analysis
Table 45. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 46. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Corporate Information, Location and Competitors
Table 48. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 49. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 50. Laboratory Corporation of America Holdings (LabCorp) (U.S.) SWOT Analysis
Table 51. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 52. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. BIOVIEW Inc. (U.S.) Corporate Information, Location and Competitors
Table 54. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 55. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 56. BIOVIEW Inc. (U.S.) SWOT Analysis
Table 57. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 58. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Gen-Probe Incorporated (U.S.) Corporate Information, Location and Competitors
Table 60. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Major Business
Table 61. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Total Revenue (USD Million) (2017-2018)
Table 62. Gen-Probe Incorporated (U.S.) SWOT Analysis
Table 63. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 64. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Noninvasive Cancer Diagnostics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Noninvasive Cancer Diagnostics Revenue Share by Players (2015-2020)
Table 67. Global Noninvasive Cancer Diagnostics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Noninvasive Cancer Diagnostics Revenue Market Share by Regions (2015-2020)
Table 69. North America Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
Table 70. North America Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Noninvasive Cancer Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Noninvasive Cancer Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Noninvasive Cancer Diagnostics Revenue by Countries (2015-2020)
Table 74. South America Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Noninvasive Cancer Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Table 77. Global Noninvasive Cancer Diagnostics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Noninvasive Cancer Diagnostics Revenue Share by Type (2015-2020)
Table 79. Global Noninvasive Cancer Diagnostics Revenue Forecast by Type (2021-2025)
Table 80. Global Noninvasive Cancer Diagnostics Revenue by Application (2015-2020)
Table 81. Global Noninvasive Cancer Diagnostics Revenue Share by Application (2015-2020)
Table 82. Global Noninvasive Cancer Diagnostics Revenue Forecast by Application (2021-2025)
Table 83. Global Noninvasive Cancer Diagnostics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Picture
Figure 2. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type in 2019
Figure 3. Clinical Chemistry Picture
Figure 4. Immunochemistry/Immunoassay Picture
Figure 5. Molecular Diagnostics Picture
Figure 6. Others Picture
Figure 7. Noninvasive Cancer Diagnostics Revenue Market Share by Application in 2019
Figure 8. Solid Tumors Picture
Figure 9. Blood Cancer Picture
Figure 10. Lung Cancer Picture
Figure 11. Breast Cancer Picture
Figure 12. Others Picture
Figure 13. Global Noninvasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Noninvasive Cancer Diagnostics Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Noninvasive Cancer Diagnostics Revenue Market Share in 2019
Figure 22. Global Top 10 Players Noninvasive Cancer Diagnostics Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Noninvasive Cancer Diagnostics Revenue Market Share by Regions (2015-2020)
Figure 26. Global Noninvasive Cancer Diagnostics Revenue Market Share by Regions in 2018
Figure 27. North America Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 28. Europe Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 30. South America Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 32. North America Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 33. North America Noninvasive Cancer Diagnostics Revenue Market Share by Countries in 2019
Figure 34. USA Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 35. Canada Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 37. Europe Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Noninvasive Cancer Diagnostics Revenue Market Share by Countries in 2019
Figure 39. Germany Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 40. UK Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 41. France Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 42. Russia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 43. Italy Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Share by Countries in 2019
Figure 46. China Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 47. Japan Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 48. Korea Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 49. India Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 51. South America Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 52. South America Noninvasive Cancer Diagnostics Revenue Market Share by Countries in 2019
Figure 53. Brazil Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 58. UAE Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Noninvasive Cancer Diagnostics Revenue and Growth Rate (2015-2020)
Figure 61. Global Noninvasive Cancer Diagnostics Revenue Share by Type (2015-2020)
Figure 62. Global Noninvasive Cancer Diagnostics Revenue Share by Type in 2019
Figure 63. Global Noninvasive Cancer Diagnostics Market Share Forecast by Type (2021-2025)
Figure 64. Global Clinical Chemistry Revenue Growth Rate (2015-2020)
Figure 65. Global Immunochemistry/Immunoassay Revenue Growth Rate (2015-2020)
Figure 66. Global Molecular Diagnostics Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Noninvasive Cancer Diagnostics Revenue Share by Application (2015-2020)
Figure 69. Global Noninvasive Cancer Diagnostics Revenue Share by Application in 2019
Figure 70. Global Noninvasive Cancer Diagnostics Market Share Forecast by Application (2021-2025)
Figure 71. Global Solid Tumors Revenue Growth Rate (2015-2020)
Figure 72. Global Blood Cancer Revenue Growth Rate (2015-2020)
Figure 73. Global Lung Cancer Revenue Growth Rate (2015-2020)
Figure 74. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 75. Global Others Revenue Growth Rate (2015-2020)
Figure 76. Global Noninvasive Cancer Diagnostics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Noninvasive Cancer Diagnostics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Noninvasive Cancer Diagnostics Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
Figure 80. Europe Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
Figure 82. South America Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel
皮膚がん診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Skin Cancer Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Skin Cancer Diagnosti…- 膀胱がん治療・診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bladder Cancer Therapeutics and Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 551.5 million by 2025, from USD 427.6 million in 2019…
- 前立腺がん診断の世界市場 2020年：メーカー別、地域別、種類・用途別 Summary Market Overview The global Prostate Cancer Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.0% in the forecast period of 2020 to 2025 and will expected to reach USD 15640 million by 2025, from USD 11940 million in 2019. The Pr…
- 次世代がん診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Next Generation Cancer Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 17.7% in the forecast period of 2020 to 2025 and will expected to reach USD 10560 million by 2025, from USD 5506.2 million in 2019. The N…
- 大腸がん診断＆治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Colorectal Cancer Diagnosis and Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The …